About
Peak 15 Bio is focused on developing breakthrough medicines for brain injury and neurological disease
Peak 15 Bio is a privately held biotechnology company, based in Dublin and Oxford, developing allogeneic, off-the-shelf cell therapies for serious neurological diseases where a treatment window exists and no adequate therapy does. Building on the Can‑Vas platform of placenta-derived endothelial colony-forming cells, we have developed proprietary methods to manufacture cryopreserved cell products ready at the point of care. Our experienced team of drug developers is working to advance first-in-class medicines for patients with significant unmet need — beginning with the newborn brain and scaling to neurological disease across the lifespan.
Leadership
Leadership Team
Peak 15 Bio was founded by experienced drug developers who have taken a rare-disease programme to Phase 3 before. We have built a focused team of scientists and operators who work tirelessly to advance cell-based medicines for the injured brain.
Management
{{ active.name }}
{{ active.role }}
{{ para }}
Governance
Board of Directors
{{ b.name }}
{{ b.role }}
{{ b.bio }}
Partner with us
We work with investors, clinicians, industry and patient communities who share our conviction that the earliest injuries deserve the most ambitious medicine.